PMN

SEC source: 0001104659-26-114106 · tm2627035-2_4seq1.xml · derivative · entry 1

Rubino Ivana · CIK 0002157418 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Shares · 80,000 shares

Expires 2036-10-05

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on October 5, 2026, with the remaining shares vesting monthly over the three (3) years thereafter, subject to continued service to the Issuer through each vesting date.

SEC source: 0001104659-26-092673 · tm2622584-1_4seq1.xml · nonDerivative · entry 1

Kaplan Johanne · CIK 0001967717 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,221

SEC source: 0001104659-26-065775 · tm2615475-9_4seq1.xml · derivative · entry 2

WYMAN WILLIAM W · CIK 0001077644 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Shares · 11,000 shares

Expires 2036-05-20

F2 · derivative.exercise_date: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

SEC source: 0001104659-26-065775 · tm2615475-9_4seq1.xml · derivative · entry 1

WYMAN WILLIAM W · CIK 0001077644 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Shares · 5,500 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

SEC source: 0001104659-26-065763 · tm2615475-3_4seq1.xml · derivative · entry 2

Mandel-Brehm Josh · CIK 0001927058 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Shares · 11,000 shares

Expires 2036-05-20

F2 · derivative.exercise_date: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

SEC source: 0001104659-26-065763 · tm2615475-3_4seq1.xml · derivative · entry 1

Mandel-Brehm Josh · CIK 0001927058 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Shares · 5,500 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

SEC source: 0001104659-26-065772 · tm2615475-7_4seq1.xml · derivative · entry 1

Warma Neil K · CIK 0001437911 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Shares · 160,000 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

SEC source: 0001104659-26-065774 · tm2615475-8_4seq1.xml · derivative · entry 2

Williams Eugene · CIK 0001927626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Shares · 11,000 shares

Expires 2036-05-20

F2 · derivative.exercise_date: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

SEC source: 0001104659-26-065774 · tm2615475-8_4seq1.xml · derivative · entry 1

Williams Eugene · CIK 0001927626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Shares · 5,500 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

SEC source: 0001104659-26-065771 · tm2615475-6_4seq1.xml · derivative · entry 2

Shafmaster Madge K. · CIK 0001927066 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Shares · 11,000 shares

Expires 2036-05-20

F2 · derivative.exercise_date: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

SEC source: 0001104659-26-065771 · tm2615475-6_4seq1.xml · derivative · entry 1

Shafmaster Madge K. · CIK 0001927066 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Shares · 5,500 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

SEC source: 0001104659-26-065769 · tm2615475-5_4seq1.xml · derivative · entry 1

Cashman Neil · CIK 0001927064 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Shares · 50,000 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

SEC source: 0001104659-26-065766 · tm2615475-4_4seq1.xml · derivative · entry 1

Milbury Max A. · CIK 0001927056 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,167

Underlying: Common Shares · 18,167 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

SEC source: 0001104659-26-065755 · tm2615475-1_4seq1.xml · derivative · entry 2

Alex Slanix Paul · CIK 0002092283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Shares · 11,000 shares

Expires 2036-05-20

F2 · derivative.exercise_date: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

SEC source: 0001104659-26-065755 · tm2615475-1_4seq1.xml · derivative · entry 1

Alex Slanix Paul · CIK 0002092283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Shares · 5,500 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

SEC source: 0001104659-26-065762 · tm2615475-2_4seq1.xml · derivative · entry 1

Kaplan Johanne · CIK 0001967717 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Shares · 50,000 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

SEC source: 0001104659-26-047977 · tm2612640-1_4seq1.xml · nonDerivative · entry 1

Kirwin Patrick D. · CIK 0001927062 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Patrick D. Kirwin Professional Corp

Disclosed balance after: 4,653

SEC source: 0001374339-26-000004 · primary_doc.xml · nonDerivative · entry 1

Williams Eugene · CIK 0001927626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,397

SEC source: 0001374339-26-000003 · primary_doc.xml · nonDerivative · entry 3

Williams Eugene · CIK 0001927626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,397

SEC source: 0001374339-26-000003 · primary_doc.xml · nonDerivative · entry 2

Williams Eugene · CIK 0001927626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,397

SEC source: 0001374339-26-000003 · primary_doc.xml · nonDerivative · entry 1

Williams Eugene · CIK 0001927626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,397

SEC source: 0001374339-26-000002 · primary_doc.xml · nonDerivative · entry 1

Kaplan Johanne · CIK 0001967717 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,941

SEC source: 0001493152-26-005410 · ownership.xml · derivative · entry 2

ABG Management Ltd. · CIK 0001832106 · 10% owner

Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner

Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner

Yu Fan · CIK 0001668029 · 10% owner

Alex Slanix Paul · CIK 0002092283 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 700,741

Underlying: Common Shares · 700,741 shares

Expires not disclosed

F1 · price: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.

F6 · derivative.exercise_date: The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.

F6 · derivative.expiration_date: The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.

F3 · ownership.nature: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.

F4 · ownership.nature: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.

F5 · ownership.nature: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.

F7 · ownership.nature: The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.

SEC source: 0001493152-26-005410 · ownership.xml · nonDerivative · entry 1

ABG Management Ltd. · CIK 0001832106 · 10% owner

Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner

Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner

Yu Fan · CIK 0001668029 · 10% owner

Alex Slanix Paul · CIK 0002092283 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 943,090

F1 · price: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.

F2 · ownership.nature: The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.

F3 · ownership.nature: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.

F4 · ownership.nature: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.

F5 · ownership.nature: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.

SEC source: 0001104659-26-011138 · tm265402-3_4seq1.xml · derivative · entry 2

Warma Neil K · CIK 0001437911 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,183

Underlying: Common Shares · 6,183 shares

Expires 2031-02-03

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F2 · derivative.expiration_date: The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-26-011138 · tm265402-3_4seq1.xml · nonDerivative · entry 1

Warma Neil K · CIK 0001437911 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,183

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

SEC source: 0001104659-26-011140 · tm265402-5_4seq1.xml · derivative · entry 4

Cashman Neil · CIK 0001927064 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Research Capital Corporation

Disclosed balance after: 4,122

Underlying: Common Shares · 4,122 shares

Expires 2031-02-03

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F3 · derivative.expiration_date: The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-26-011140 · tm265402-5_4seq1.xml · nonDerivative · entry 1

Cashman Neil · CIK 0001927064 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Research Capital Corporation

Disclosed balance after: 4,122

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

SEC source: 0001104659-26-011139 · tm265402-4_4seq1.xml · derivative · entry 2

Kaplan Johanne · CIK 0001967717 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,060

Underlying: Common Shares · 2,060 shares

Expires 2031-02-03

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F3 · derivative.expiration_date: The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-26-011139 · tm265402-4_4seq1.xml · nonDerivative · entry 1

Kaplan Johanne · CIK 0001967717 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,312

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F2 · balance_after: Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

SEC source: 0001104659-26-011137 · tm265402-2_4seq1.xml · derivative · entry 2

Milbury Max A. · CIK 0001927056 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,595

Underlying: Common Shares · 6,595 shares

Expires 2031-02-03

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F3 · derivative.expiration_date: The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-26-011137 · tm265402-2_4seq1.xml · nonDerivative · entry 1

Milbury Max A. · CIK 0001927056 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,409

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F2 · balance_after: Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

SEC source: 0001104659-26-011135 · tm265402d1_4seq1.xml · derivative · entry 4

Kirwin Patrick D. · CIK 0001927062 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,050

Underlying: Common Shares · 3,050 shares

Expires 2031-02-03

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F3 · derivative.expiration_date: The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

SEC source: 0001104659-26-011135 · tm265402d1_4seq1.xml · nonDerivative · entry 1

Kirwin Patrick D. · CIK 0001927062 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,135

F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

F2 · balance_after: Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

SEC source: 0001493152-25-019320 · ownership.xml · derivative · entry 1

ABG Management Ltd. · CIK 0001832106 · 10% owner

Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner

Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner

Yu Fan · CIK 0001668029 · 10% owner

Alex Slanix Paul · CIK 0002092283 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Shares · 40,000 shares

Expires 2035-10-22

F1 · derivative.exercise_date: 25% of the shares subject to this option vested on the date of grant and the remaining shares shall vest in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

F2 · ownership.direct: This option was granted to Slanix Alex, a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. Dr. Alex holds any equity-based compensation awarded to him for his service as a director of the Issuer for the benefit of Ally Bridge MedAlpha Master Fund L.P. Any proceeds from the sale of shares upon exercise of this award shall be remitted to Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose.

SEC source: 0001927056-25-000004 · primary_doc.xml · nonDerivative · entry 1

Milbury Max A. · CIK 0001927056 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,389

SEC source: 0001437911-25-000002 · primary_doc.xml · derivative · entry 1

Warma Neil K · CIK 0001437911 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Shares · 600,000 shares

Expires 2035-09-22

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

SEC source: 0001927056-25-000003 · primary_doc.xml · derivative · entry 1

Milbury Max A. · CIK 0001927056 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Shares · 60,000 shares

Expires 2035-09-22

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

SEC source: 0001927064-25-000002 · primary_doc.xml · derivative · entry 1

Cashman Neil · CIK 0001927064 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Shares · 165,000 shares

Expires 2035-09-22

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

SEC source: 0001967717-25-000002 · primary_doc.xml · derivative · entry 1

Kaplan Johanne · CIK 0001967717 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Shares · 165,000 shares

Expires 2035-09-22

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

SEC source: 0001619444-25-000002 · primary_doc.xml · derivative · entry 1

ALTSTIEL LARRY DOUGLAS · CIK 0001619444 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Shares · 165,000 shares

Expires 2035-09-22

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

SEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · derivative · entry 7

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 539,100

Underlying: Common Shares · 539,100 shares

Expires not disclosed

F5 · derivative.exercise_price: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

F5 · price: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

F5 · derivative.exercise_date: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

F5 · derivative.expiration_date: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-071857 · tm2521929-1_4seq1.xml · derivative · entry 7

Title 19 Promis · CIK 0002005531 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,100

Underlying: Common Shares · 539,100 shares

Expires not disclosed

F4 · derivative.exercise_price: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

F4 · price: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

F4 · derivative.exercise_date: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

F4 · derivative.expiration_date: On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

SEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · derivative · entry 9

Sclar Jeremy M. · CIK 0001955608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 3,139,533

Underlying: Common Shares · 3,139,533 shares

Expires not disclosed

F6 · derivative.exercise_price: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

F6 · price: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

F6 · derivative.exercise_date: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

F6 · derivative.expiration_date: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

SEC source: 0001104659-25-095035 · tm2523607-3_4seq1.xml · derivative · entry 7

Jeremy M. Sclar 2012 Irrevocable Family Trust · CIK 0002089163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,139,533

Underlying: Common Shares · 3,139,533 shares

Expires not disclosed

F4 · derivative.exercise_price: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

F4 · price: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

F4 · derivative.exercise_date: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

F4 · derivative.expiration_date: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

SEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · derivative · entry 6

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F4 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F4 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F4 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · derivative · entry 5

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F3 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F3 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F3 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · derivative · entry 4

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 345,316

Underlying: Common Shares · 119,800 shares

Expires not disclosed

F1 · derivative.exercise_price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F1 · derivative.exercise_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F1 · derivative.expiration_date: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · nonDerivative · entry 3

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Title 19 Promis

Disclosed balance after: 2,435,029

F4 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F4 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

SEC source: 0001104659-25-071858 · tm2521929-2_4seq1.xml · nonDerivative · entry 2

GORDON MICHAEL S · CIK 0001034608 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Title 19 Promis

Disclosed balance after: 2,315,229

F3 · kind: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F3 · price: On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

F2 · ownership.nature: By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.